

RECEIVED  
CENTRAL FAX CENTER

FEB 02 2007

## BEST AVAILABLE COPY

Application No.: 10/748010

Case No.: 58281US004

Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

What is Claimed is:

1. (Currently amended) An immunostimulatory combination comprising:  
a Toll-Like Receptor (TLR) agonist; and  
a ~~TNF/R~~ CD40 agonist or a 4-1BB agonist;  
each in an amount that, in combination with the other, is effective to produce a synergistic increase in a subject's immune response to an antigen.
2. (Original) The immunostimulatory combination of claim 1 wherein the TLR agonist is an agonist of at least one of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, or any combination of any of the foregoing.
3. (Currently amended) The immunostimulatory combination of claim 2 wherein the TLR agonist comprises an immune response modifier (IRM) compound or an agonist of TLR2.
4. (Currently amended) The immunostimulatory combination of claim 1 wherein the TLR agonist comprises an IRM compound, MALP-2, Pam3cys, LPS, polyIC, CpG, or any combination of any of the foregoing.
5. (Currently amended) The immunostimulatory combination of claim 1 wherein the TLR agonist ~~3~~ ~~wherein the IRM compound~~ comprises an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphthyridine amine, or a thiazolonaphthyridine amine.

## BEST AVAILABLE COPY

Application No.: 10/748010

Case No.: 58281US004

6. (Withdrawn) The immunostimulatory combination of claim 1 wherein the TNF/R agonist comprises an agonist of a TNF Superfamily member.
7. (Withdrawn) The immunostimulatory combination of claim 6 wherein the TNF/R agonist comprises an agonist of CD40 ligand, OX40 ligand, 4-1BB ligand, CD27, CD30 ligand (CD153), TNF- $\alpha$ , TNF- $\beta$ , RANK ligand, LT- $\alpha$ , LT- $\beta$ , GITR ligand, or LIGHT
8. (Currently amended) The immunostimulatory combination of claim 1 wherein the 4-1BB TNF/R agonist comprises an agonist of a TNFR Superfamily member agonistic antibody.
9. (Currently amended) The immunostimulatory combination of claim 1 & wherein the TNF/R CD40 agonist comprises an anti-CD40 antibody or a receptor binding domain of CD40 ligand. ~~an agonist of CD40, OX40, 4-1BB, CD70 (CD27 ligand), CD30, TNFR2, RANK, LT- $\beta$ R, HVEM, GITR, TROY, or RELT.~~
10. (Currently amended) The immunostimulatory combination of claim 1 wherein the ~~TNF/R~~ CD40 agonist comprises an agonistic antibody.
11. (Withdrawn) A method of inducing a T<sub>H</sub>1 immune response in a subject comprising:  
co-administering to the subject a TLR agonist and a TNF/R agonist, each in an amount that, when in combination with the other, is effective to induce a T<sub>H</sub>1 immune response.
12. (Withdrawn) The method of claim 11 wherein the TLR agonist comprises an agonist of TLR2.
13. (Withdrawn) The method of claim 11 wherein the TLR agonist comprises an agonist of TLR9.

**BEST AVAILABLE COPY**

Application No.: 10/748010

Case No.: 58281US004

14. (Withdrawn) The method of claim 11 wherein the TLR agonist comprises an agonist of TLR8.
15. (Withdrawn) The method of claim 11 wherein the TLR agonist comprises an agonist of TLR7.
16. (Withdrawn) The method of claim 11 further comprising co-administering an antigen in an amount effective to induce an immune response in the subject.
17. (Withdrawn) A method of activating antigen-specific CD8<sup>+</sup> T cells in a subject comprising:  
co-administering to the subject a TLR agonist and a TNF/R agonist, each in an amount that, in combination with the other, is effective to activate antigen-specific CD8<sup>+</sup> T cells.
18. (Withdrawn) The method of claim 17 further comprising co-administering an antigen in an amount effective to induce an immune response in the subject.
19. (Withdrawn) The method of claim 17 wherein activating CD8<sup>+</sup> T cells comprises expansion of CD8<sup>+</sup> effector T cells.
20. (Withdrawn) The method of claim 17 wherein activating CD8<sup>+</sup> T cells comprises generating CD8<sup>+</sup> memory T cells.
21. (Withdrawn) The method of claim 17 wherein the TLR agonist comprises an agonist of TLR2.
22. (Withdrawn) The method of claim 17 wherein the TLR agonist comprises an agonist of TLR9.

**BEST AVAILABLE COPY**

Application No.: 10/748010

Case No.: 58281US004

23. (Withdrawn) The method of claim 17 wherein the TLR agonist comprises an agonist of TLR8.
24. (Withdrawn) The method of claim 17 wherein the TLR agonist comprises an agonist of TLR7.
25. (Withdrawn) The method of claim 17 wherein the TNF/R agonist comprises an agonist of a TNF Superfamily member.
26. (Withdrawn) The method of claim 17 wherein the TNF/R agonist comprises an agonist of a TNFR Superfamily member.
27. (Withdrawn) The method of claim 17 wherein the TNF/R agonist comprises an agonistic antibody.
28. (Withdrawn) A method of activating antigen-specific memory CD8<sup>+</sup> T cells in a subject having prior exposure to an antigen, comprising:  
administering to the subject the antigen in an amount effective to induce antigen-specific CD8<sup>+</sup> memory T cells to become activated, thereby generating antigen-specific CD8<sup>+</sup> effector T cells.
29. (Withdrawn) The method of claim 28 further comprising co-administering a TLR agonist in an amount effective to induce antigen-specific CD8<sup>+</sup> memory T cells to become activated, thereby generating antigen-specific CD8<sup>+</sup> effector T cells.
30. (Withdrawn) The method of claim 28 wherein the TLR agonist comprises an agonist of TLR2.
31. (Withdrawn) The method of claim 28 wherein the TLR agonist comprises an agonist of TLR9.

**BEST AVAILABLE COPY**

Application No.: 10/748010

Case No.: 58281US004

32. (Withdrawn) The method of claim 28 wherein the TLR agonist comprises an agonist of TLR8.
33. (Withdrawn) The method of claim 28 wherein the TLR agonist comprises an agonist of TLR7.
34. (Withdrawn) A method of treating a condition in a subject comprising:  
co-administering to the subject a TLR agonist and a TNF/R agonist, each administered in an amount that, when in combination with the other, is effective for stimulating a cell-mediated immune response.
35. (Withdrawn) The method of claim 34 wherein the TLR agonist comprises an agonist of TLR2.
36. (Withdrawn) The method of claim 34 wherein the TLR agonist comprises an agonist of TLR9.
37. (Withdrawn) The method of claim 34 wherein the TLR agonist comprises an agonist of TLR8.
38. (Withdrawn) The method of claim 34 wherein the TLR agonist comprises an agonist of TLR7.
39. (Withdrawn) The method of claim 34 wherein the TNF/R agonist comprises an agonist of a TNF Superfamily member.
40. (Withdrawn) The method of claim 34 wherein the TNF/R agonist comprises an agonist of a TNFR Superfamily member.

## BEST AVAILABLE COPY

Application No.: 10/748010

Case No.: 58281US004

41. (Withdrawn) The method of claim 34 wherein the TNF/R agonist comprises an agonistic antibody.
42. (Withdrawn) The method of claim 34 further comprising co-administering an antigen associated with the condition in an amount effective for inducing a cell-mediated immune response.
43. (Withdrawn) The method of claim 34 wherein the condition comprises a neoplastic disease.
44. (Withdrawn) The method of claim 43 wherein co-administering the TLR agonist and the TNF/R agonist provides prophylactic treatment.
45. (Withdrawn) The method of claim 43 wherein co-administering the TLR agonist and the TNF/R agonist provides therapeutic treatment.
46. (Withdrawn) The method of claim 34 wherein the condition comprises an infectious disease.
47. (Withdrawn) The method of claim 46 wherein co-administering the TLR agonist and the TNF/R agonist provides prophylactic treatment.
48. (Withdrawn) The method of claim 46 wherein co-administering the TLR agonist and the TNF/R agonist provides therapeutic treatment.
49. (Currently amended) A vaccine comprising:  
a TLR agonist;  
a ~~TNF/R~~ CD40 agonist or a 4-1BB agonist; and  
an antigen;

## BEST AVAILABLE COPY

Application No.: 10/748010

Case No.: 58281US004

each in an amount that, in combination with the others, is effective for inducing ~~an a~~ synergistic immune response to the antigen in a subject immunized with the vaccine.

50. (Withdrawn) The vaccine of claim 49 wherein the TLR agonist comprises an agonist of TLR2.
51. (Withdrawn) The vaccine of claim 49 wherein the TLR agonist comprises an agonist of TLR9.
52. (Withdrawn) The vaccine of claim 49 wherein the TLR agonist comprises an agonist of TLR8.
53. (Original) The vaccine of claim 49 wherein the TLR agonist comprises an agonist of TLR7.
54. (Withdrawn) The vaccine of claim 49 wherein the TNF/R agonist comprises an agonist of a TNF Superfamily member.
55. (Currently amended) The vaccine of claim 49 wherein the ~~TNF/R~~ 4-1BB agonist comprises an ~~agonist of a TNFR Superfamily member~~ agonistic antibody.
56. (Currently amended) The vaccine of claim 49 wherein the ~~TNF/R~~ CD40 agonist comprises an agonistic antibody.
57. (Original) The vaccine of claim 49 wherein the antigen comprises a tumor antigen, a viral antigen, a bacterial antigen, or a parasitic antigen.